For years, veterans with polyneuropathy caused by amyloidosis have faced barriers to receiving the right treatment. The Veterans’ Administration formulary required patients to try medications intended for cardiomyopathy before they could access therapy indicated for polyneuropathy.
The delay meant unnecessary suffering for many, as polyneuropathy and cardiomyopathy represent two distinct presentations of amyloidosis, each requiring unique treatment approaches. With the recent update to the VA formulary, this “fail first” restriction has been removed, offering veterans access to the right treatment sooner.
Understanding Amyloidosis
Amyloidosis causes abnormal proteins to be produced, and eventually build up in tissues and organs, interfering with normal function. The disease takes different forms, with hereditary transthyretin-mediated (ATTR) amyloidosis often affecting the nerves – called polyneuropathy – or the heart – called cardiomyopathy. Other presentations can impact the kidneys, liver, brain, bowel and lungs.
Early diagnosis and intervention are essential to protect patients. Left untreated, amyloidosis can lead to progressive disability and worsening symptoms, driving down quality of life.